<DOC>
	<DOCNO>NCT01565083</DOCNO>
	<brief_summary>This two-cohort , open-label , multicenter , phase 2 study ass safety efficacy pertuzumab give combination trastuzumab ( Herceptin ) vinorelbine first line participant metastatic locally advanced HER2-positive breast cancer . Participants receive pertuzumab trastuzumab administer sequentially separate intravenous ( IV ) infusion ( follow vinorelbine ) conventional sequential administration pertuzumab trastuzumab separate infusion bag , follow vinorelbine .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Pertuzumab Given Combination With Trastuzumab Vinorelbine Participants With Metastatic Locally Advanced Human Epidermal Growth Factor Receptor ( HER ) 2-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm documented adenocarcinoma breast metastatic locally advanced disease amenable curative resection HER2positive assess local laboratory primary metastatic tumor At least one measurable lesion and/or nonmeasurable disease evaluable accord RECIST v1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Left ventricular ejection fraction ( LVEF ) least 55 % Life expectancy least 12 week Previous systemic nonhormonal anticancer therapy metastatic locally advanced breast cancer set Previous approve investigative antiHER2 agent breast cancer treatment set , except trastuzumab and/or lapatinib adjuvant neoadjuvant set Disease progression receive trastuzumab and/or lapatinib adjuvant neoadjuvant set Diseasefree interval completion adjuvant neoadjuvant systemic nonhormonal treatment recurrent disease le 6 month History persistent Grade 2 high ( National Cancer Institute Common Terminology Criteria [ NCICTC ] , Version 4.0 ) hematological toxicity result previous adjuvant neoadjuvant therapy Radiographic evidence central nervous system metastasis well control local therapy ( irradiation surgery ) Current peripheral neuropathy NCICTC , version 4.0 Grade 3 great History malignancy within last 5 year , except carcinoma situ cervix , nonmelanoma skin carcinoma , Stage 1 uterine cancer , cancer similar curative outcome mention Serious uncontrolled concomitant disease would contraindicate use investigational drug use study would put participant high risk treatmentrelated complication Inadequate hematologic , liver , renal function Uncontrolled hypertension clinically significant cardiovascular disease Hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) infection Current chronic daily treatment corticosteroid ( &gt; /= 10 mg/day methylprednisolone equivalent ) , exclude inhaled steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>